Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cellular and vaccine therapeutic approaches for gliomas.

Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA.

J Transl Med. 2010 Oct 14;8:100. doi: 10.1186/1479-5876-8-100. Review.

2.

Dendritic-cell- and peptide-based vaccination strategies for glioma.

Yamanaka R.

Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273. doi: 10.1007/s10143-009-0189-1. Review.

PMID:
19214609
3.

Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J.

Neurosurg Rev. 2008 Apr;31(2):141-55; discussion 155. doi: 10.1007/s10143-008-0121-0. Review.

4.

Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.

Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB.

Cancer Invest. 2014 Nov;32(9):451-7. doi: 10.3109/07357907.2014.958234. Review.

PMID:
25259676
5.

Peptide vaccine therapy for childhood gliomas.

Pollack IF, Jakacki RI, Butterfield LH, Okada H.

Neurosurgery. 2013 Aug;60 Suppl 1:113-9. doi: 10.1227/01.neu.0000430769.33467.68. Review. No abstract available.

PMID:
23839362
6.

Dendritic cell immunotherapy for malignant gliomas.

Luptrawan A, Liu G, Yu JS.

Rev Recent Clin Trials. 2008 Jan;3(1):10-21. Review.

PMID:
18474011
7.

Dendritic cell therapy of high-grade gliomas.

Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S.

Brain Pathol. 2009 Oct;19(4):694-712. doi: 10.1111/j.1750-3639.2009.00316.x. Review.

PMID:
19744041
8.

Peptide-based immunotherapeutic approaches to glioma: a review.

Yamanaka R, Itoh K.

Expert Opin Biol Ther. 2007 May;7(5):645-9. Review.

PMID:
17477802
9.

[Treatment of the glioma microenvironment].

Herrlinger U, Platten M.

Nervenarzt. 2015 Jun;86(6):684, 686-8, 690-1. doi: 10.1007/s00115-014-4225-1. Review. German.

PMID:
25962344
10.

Vaccine therapies in malignant glioma.

Oh T, Sayegh ET, Fakurnejad S, Oyon D, Lamano JB, DiDomenico JD, Bloch O, Parsa AT.

Curr Neurol Neurosci Rep. 2015 Jan;15(1):508. doi: 10.1007/s11910-014-0508-y. Review.

11.

Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials.

van Gool S.

Immunotherapy. 2013 Oct;5(10):1043-6. doi: 10.2217/imt.13.86.

PMID:
24138559
12.

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, Ashizawa T, Yagoto M, Abe Y, Mitsuya K, Watanabe R, Sugino T, Yamaguchi K, Nakasu Y.

BMC Cancer. 2012 Dec 27;12:623. doi: 10.1186/1471-2407-12-623.

13.

Immunotherapy for malignant gliomas.

Bloch O.

Cancer Treat Res. 2015;163:143-58. doi: 10.1007/978-3-319-12048-5_9. Review.

PMID:
25468230
14.

Dendritic cell vaccines and immunity in glioma patients.

Wheeler CJ, Black KL.

Front Biosci. 2005 Sep 1;10:2861-81. Review.

PMID:
15970541
15.

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, Grecula J, Newton H, Harris KS, Grossman RG, Trask TW, Baskin DS, Monterroso C, Manzanera AG, Aguilar-Cordova E, New PZ.

J Clin Oncol. 2011 Sep 20;29(27):3611-9. doi: 10.1200/JCO.2011.35.5222.

16.

[CTL precursor-oriented peptide vaccine therapy for malignant glioma].

Yajima N, Yamanaka R, Tanaka R, Shigemori M, Mine T, Itoh K.

Nihon Rinsho. 2005 Sep;63 Suppl 9:582-7. Review. Japanese. No abstract available.

PMID:
16201585
17.

Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.

Mitra S, Li G, Harsh GR 4th.

Neurosurg Clin N Am. 2010 Jan;21(1):67-76. doi: 10.1016/j.nec.2009.08.010. Review.

PMID:
19944967
18.

Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE.

Anticancer Agents Med Chem. 2010 Jul;10(6):462-70. Review.

19.

[Peptide vaccination therapy for malignant glioma].

Yamanaka R, Itoh K.

Brain Nerve. 2007 Mar;59(3):251-61. Review. Japanese.

PMID:
17370651
20.

Immunotherapy approaches for malignant glioma from 2007 to 2009.

Johnson LA, Sampson JH.

Curr Neurol Neurosci Rep. 2010 Jul;10(4):259-66. doi: 10.1007/s11910-010-0111-9. Review.

Items per page

Supplemental Content

Support Center